At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02179 RECBIO-B
Not Yet Opened 05-11 16:00:00
5.170
-0.010
-0.19%
High5.170
Low5.170
Vol0.00
Open5.170
D1 Closing5.180
Amplitude0.00%
Mkt Cap3.24B
Tradable Cap2.37B
Total Shares626.00M
T/O0.00
T/O Rate0.00%
Tradable Shares458.09M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Recbio Converts 141.95 Million Shares into H Shares, Optimising Capital Structure and Hong Kong Float
Jiangsu Recbio Technology Co Ltd is a China-based company engaged in vaccine research and development. The Company is still in the research and development stage. The Company's vaccine pipeline includes recombinant human papillomavirus (HPV) 9-valent vaccine, novel adjuvanted recombinant HPV 9-valent vaccine, recombinant HPV bivalent (Types 16/18) vaccine, recombinant HPV bivalent (Types 6/11) vaccine, novel adjuvanted recombinant HPV quadrivalent vaccine, novel adjuvanted recombinant shingles vaccine, novel adjuvanted recombinant respiratory syncytial virus vaccine, recombinant metapneumovirus vaccine, recombinant human cytomegalovirus vaccine, recombinant bicomponent COVID-19 vaccine, recombinant hepatitis B virus vaccine, and others.